Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRISPR-Cas9
Biotech
Vertex pays Editas $100M to use gene-editing tech
After an FDA nod for its SCD gene therapy, Vertex is paying $100M for rights to Editas’ Cas9 tech amid a long-running patent battle.
Gabrielle Masson
Dec 13, 2023 12:46pm
CRISPR Therapeutics laid off staff a week after positive AdComm
Nov 22, 2023 1:36pm
FDA advisers wave through first CRISPR-based therapy
Nov 1, 2023 11:07am
CRISPR-Vertex gene editing 1st gets narrow review by FDA panel
Oct 27, 2023 11:20am
CRISPR on hunt for pipeline partners and enticing delivery tech
Oct 19, 2023 10:35am
Intellia preps first ph. 3 trial of in vivo CRISPR therapy in US
Oct 18, 2023 10:15am